Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Shaopei Chen
Introduction
Shaopei Chen is a notable inventor based in Guangdong, China. He has made significant strides in the field of biotechnology, particularly in the development of T cell receptors for cancer therapy. His work focuses on enhancing the recognition of specific antigens, which is crucial for targeted cancer treatments.
Latest Patents
Shaopei Chen holds a patent for a high affinity cell receptor designed to recognize the AFP antigen. This invention provides a T cell receptor (TCR) that binds to a FMNKFIYEI-HLA A0201 complex. The binding affinity of this TCR is at least two times greater than that of the wild-type TCR to the same complex. Additionally, the patent includes a fusion molecule of such TCRs with therapeutic agents, allowing for targeted therapy against tumor cells presenting the FMNKFIYEI-HLA A0201 complex.
Career Highlights
Shaopei Chen is associated with Xlifesc, Ltd., where he continues to advance his research and development efforts. His innovative approach to T cell receptor design has the potential to significantly impact cancer treatment methodologies.
Collaborations
Shaopei Chen collaborates with talented individuals such as Yi Li and Xiaolin Li, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Shaopei Chen's contributions to the field of biotechnology, particularly through his patented T cell receptor technology, exemplify the importance of innovation in cancer therapy. His work not only enhances our understanding of immune responses but also paves the way for more effective treatments for patients.